Enimmune corporation
Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, includ… Read more
Enimmune corporation (6564) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.450x
Based on the latest financial reports, Enimmune corporation (6564) has a cash flow conversion efficiency ratio of -0.450x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-101.06 Million) by net assets (NT$224.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enimmune corporation - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Enimmune corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Enimmune corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enimmune corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Malaysia Airport Holdings Bhd
KLSE:5014
|
0.104x |
|
Pro Inside Public Company Limited
BK:PIS
|
-0.196x |
|
Chang Jia M&E Engineering
TWO:4550
|
-0.028x |
|
Leaders Technology Investment Co. Ltd
KQ:019570
|
-0.063x |
|
LEMONSOFT EO 1
F:M36
|
N/A |
|
Mahindra EPC Irrigation Limited
NSE:MAHEPC
|
-0.060x |
|
0DG8
LSE:0DG8
|
N/A |
|
SAI.TECH Global Corporation
NASDAQ:SAI
|
0.032x |
Annual Cash Flow Conversion Efficiency for Enimmune corporation (2019–2024)
The table below shows the annual cash flow conversion efficiency of Enimmune corporation from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$479.20 Million | NT$-143.78 Million | -0.300x | +6.31% |
| 2023-12-31 | NT$431.36 Million | NT$-138.13 Million | -0.320x | -6.20% |
| 2022-12-31 | NT$665.41 Million | NT$-200.64 Million | -0.302x | -140.22% |
| 2021-12-31 | NT$570.03 Million | NT$-71.55 Million | -0.126x | +27.87% |
| 2020-12-31 | NT$617.27 Million | NT$-107.42 Million | -0.174x | +6.00% |
| 2019-12-31 | NT$323.66 Million | NT$-59.92 Million | -0.185x | -- |